nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—autistic disorder—Clonazepam—epilepsy syndrome	0.24	1	CpDpCtD
Atomoxetine—SLC6A4—epilepsy syndrome	0.051	0.292	CbGaD
Atomoxetine—CYP2C19—epilepsy syndrome	0.0483	0.277	CbGaD
Atomoxetine—HTR2A—epilepsy syndrome	0.0392	0.225	CbGaD
Atomoxetine—CYP2D6—epilepsy syndrome	0.0358	0.206	CbGaD
Atomoxetine—Protriptyline—Carbamazepine—epilepsy syndrome	0.0191	0.0787	CrCrCtD
Atomoxetine—Warfarin—Phenytoin—epilepsy syndrome	0.0167	0.0688	CrCrCtD
Atomoxetine—Indecainide—Oxcarbazepine—epilepsy syndrome	0.0166	0.0684	CrCrCtD
Atomoxetine—Phenindione—Fosphenytoin—epilepsy syndrome	0.0163	0.0674	CrCrCtD
Atomoxetine—Warfarin—Oxcarbazepine—epilepsy syndrome	0.0142	0.0585	CrCrCtD
Atomoxetine—Phenprocoumon—Phenytoin—epilepsy syndrome	0.0141	0.0581	CrCrCtD
Atomoxetine—Modafinil—Fosphenytoin—epilepsy syndrome	0.0137	0.0564	CrCrCtD
Atomoxetine—Nortriptyline—Oxcarbazepine—epilepsy syndrome	0.0115	0.0476	CrCrCtD
Atomoxetine—Phenindione—Phenytoin—epilepsy syndrome	0.0112	0.0462	CrCrCtD
Atomoxetine—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.011	0.0673	CbGbCtD
Atomoxetine—Phenindione—Carbamazepine—epilepsy syndrome	0.0103	0.0426	CrCrCtD
Atomoxetine—CYP2C19—Felbamate—epilepsy syndrome	0.0102	0.0626	CbGbCtD
Atomoxetine—CYP2C19—Trimethadione—epilepsy syndrome	0.0102	0.0626	CbGbCtD
Atomoxetine—Desipramine—Carbamazepine—epilepsy syndrome	0.00977	0.0403	CrCrCtD
Atomoxetine—CYP2C19—Fosphenytoin—epilepsy syndrome	0.00958	0.0589	CbGbCtD
Atomoxetine—Phenindione—Oxcarbazepine—epilepsy syndrome	0.00951	0.0393	CrCrCtD
Atomoxetine—Benzyl Benzoate—Fosphenytoin—epilepsy syndrome	0.00951	0.0393	CrCrCtD
Atomoxetine—Modafinil—Phenytoin—epilepsy syndrome	0.00936	0.0386	CrCrCtD
Atomoxetine—Phenindione—Clobazam—epilepsy syndrome	0.00912	0.0376	CrCrCtD
Atomoxetine—Desipramine—Oxcarbazepine—epilepsy syndrome	0.009	0.0372	CrCrCtD
Atomoxetine—Modafinil—Carbamazepine—epilepsy syndrome	0.00864	0.0357	CrCrCtD
Atomoxetine—CYP2C19—Clobazam—epilepsy syndrome	0.00831	0.051	CbGbCtD
Atomoxetine—Modafinil—Oxcarbazepine—epilepsy syndrome	0.00796	0.0328	CrCrCtD
Atomoxetine—Benzphetamine—Phenytoin—epilepsy syndrome	0.00704	0.029	CrCrCtD
Atomoxetine—CYP2C19—Carbamazepine—epilepsy syndrome	0.00688	0.0423	CbGbCtD
Atomoxetine—Benzyl Benzoate—Phenytoin—epilepsy syndrome	0.00652	0.0269	CrCrCtD
Atomoxetine—CYP2C19—Primidone—epilepsy syndrome	0.00643	0.0395	CbGbCtD
Atomoxetine—Diphenhydramine—Phenytoin—epilepsy syndrome	0.00625	0.0258	CrCrCtD
Atomoxetine—CYP2C19—Phenytoin—epilepsy syndrome	0.00617	0.0379	CbGbCtD
Atomoxetine—Benzyl Benzoate—Carbamazepine—epilepsy syndrome	0.00602	0.0248	CrCrCtD
Atomoxetine—CYP2C19—Propofol—epilepsy syndrome	0.00576	0.0354	CbGbCtD
Atomoxetine—CYP2C19—Phenobarbital—epilepsy syndrome	0.0055	0.0338	CbGbCtD
Atomoxetine—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0053	0.0326	CbGbCtD
Atomoxetine—CYP2C19—Diazepam—epilepsy syndrome	0.00522	0.032	CbGbCtD
Atomoxetine—CYP2C19—Zonisamide—epilepsy syndrome	0.00509	0.0313	CbGbCtD
Atomoxetine—CYP3A4—Felbamate—epilepsy syndrome	0.00493	0.0303	CbGbCtD
Atomoxetine—CYP3A4—Trimethadione—epilepsy syndrome	0.00493	0.0303	CbGbCtD
Atomoxetine—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00463	0.0285	CbGbCtD
Atomoxetine—CYP2D6—Propofol—epilepsy syndrome	0.00438	0.0269	CbGbCtD
Atomoxetine—CYP3A4—Clonazepam—epilepsy syndrome	0.00419	0.0257	CbGbCtD
Atomoxetine—CYP2C19—Valproic Acid—epilepsy syndrome	0.00411	0.0253	CbGbCtD
Atomoxetine—CYP3A4—Clobazam—epilepsy syndrome	0.00402	0.0247	CbGbCtD
Atomoxetine—CYP2C19—Topiramate—epilepsy syndrome	0.00371	0.0228	CbGbCtD
Atomoxetine—HTR1D—meninx—epilepsy syndrome	0.00369	0.11	CbGeAlD
Atomoxetine—CYP3A4—Rufinamide—epilepsy syndrome	0.00342	0.021	CbGbCtD
Atomoxetine—CYP3A4—Carbamazepine—epilepsy syndrome	0.00333	0.0204	CbGbCtD
Atomoxetine—CYP3A4—Primidone—epilepsy syndrome	0.00311	0.0191	CbGbCtD
Atomoxetine—CYP3A4—Phenytoin—epilepsy syndrome	0.00298	0.0183	CbGbCtD
Atomoxetine—CYP3A4—Propofol—epilepsy syndrome	0.00278	0.0171	CbGbCtD
Atomoxetine—CYP3A4—Phenobarbital—epilepsy syndrome	0.00266	0.0163	CbGbCtD
Atomoxetine—CYP3A4—Acetazolamide—epilepsy syndrome	0.00266	0.0163	CbGbCtD
Atomoxetine—CYP3A4—Midazolam—epilepsy syndrome	0.00262	0.0161	CbGbCtD
Atomoxetine—CYP3A4—Diazepam—epilepsy syndrome	0.00252	0.0155	CbGbCtD
Atomoxetine—CYP3A4—Zonisamide—epilepsy syndrome	0.00246	0.0151	CbGbCtD
Atomoxetine—CYP3A4—Valproic Acid—epilepsy syndrome	0.00199	0.0122	CbGbCtD
Atomoxetine—HTR2A—phrenic nerve—epilepsy syndrome	0.00198	0.0589	CbGeAlD
Atomoxetine—CYP3A4—Topiramate—epilepsy syndrome	0.00179	0.011	CbGbCtD
Atomoxetine—SLC6A2—locus ceruleus—epilepsy syndrome	0.00147	0.0438	CbGeAlD
Atomoxetine—HTR6—ganglion—epilepsy syndrome	0.000901	0.0268	CbGeAlD
Atomoxetine—HTR2A—locus ceruleus—epilepsy syndrome	0.000885	0.0263	CbGeAlD
Atomoxetine—HTR1B—telencephalic ventricle—epilepsy syndrome	0.000873	0.0259	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.000865	0.0257	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—epilepsy syndrome	0.000845	0.0251	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—epilepsy syndrome	0.000837	0.0249	CbGeAlD
Atomoxetine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.000782	0.0233	CbGeAlD
Atomoxetine—HTR2A—cerebellar cortex—epilepsy syndrome	0.000721	0.0214	CbGeAlD
Atomoxetine—HTR2A—vagus nerve—epilepsy syndrome	0.000677	0.0201	CbGeAlD
Atomoxetine—HTR1B—ganglion—epilepsy syndrome	0.000543	0.0161	CbGeAlD
Atomoxetine—SLC6A3—ganglion—epilepsy syndrome	0.000539	0.016	CbGeAlD
Atomoxetine—NPY1R—forebrain—epilepsy syndrome	0.000537	0.016	CbGeAlD
Atomoxetine—HTR1D—ganglion—epilepsy syndrome	0.000526	0.0156	CbGeAlD
Atomoxetine—HTR2C—ganglion—epilepsy syndrome	0.000521	0.0155	CbGeAlD
Atomoxetine—HTR2A—pons—epilepsy syndrome	0.00051	0.0152	CbGeAlD
Atomoxetine—NPY1R—telencephalon—epilepsy syndrome	0.000494	0.0147	CbGeAlD
Atomoxetine—SLC6A4—ganglion—epilepsy syndrome	0.000494	0.0147	CbGeAlD
Atomoxetine—HTR2A—autonomic nervous system—epilepsy syndrome	0.00047	0.014	CbGeAlD
Atomoxetine—SLC6A2—ganglion—epilepsy syndrome	0.000435	0.0129	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—epilepsy syndrome	0.00042	0.0125	CbGeAlD
Atomoxetine—SLC6A3—hindbrain—epilepsy syndrome	0.000409	0.0121	CbGeAlD
Atomoxetine—HTR6—forebrain—epilepsy syndrome	0.000378	0.0112	CbGeAlD
Atomoxetine—SLC6A4—hindbrain—epilepsy syndrome	0.000374	0.0111	CbGeAlD
Atomoxetine—HTR6—telencephalon—epilepsy syndrome	0.000348	0.0103	CbGeAlD
Atomoxetine—NPY1R—head—epilepsy syndrome	0.000308	0.00914	CbGeAlD
Atomoxetine—NPY1R—nervous system—epilepsy syndrome	0.000292	0.00867	CbGeAlD
Atomoxetine—NPY1R—central nervous system—epilepsy syndrome	0.000281	0.00834	CbGeAlD
Atomoxetine—HTR2A—ganglion—epilepsy syndrome	0.000261	0.00776	CbGeAlD
Atomoxetine—HTR1B—brainstem—epilepsy syndrome	0.000236	0.00702	CbGeAlD
Atomoxetine—SLC6A3—brainstem—epilepsy syndrome	0.000234	0.00696	CbGeAlD
Atomoxetine—HTR1D—brainstem—epilepsy syndrome	0.000229	0.00679	CbGeAlD
Atomoxetine—HTR1B—forebrain—epilepsy syndrome	0.000228	0.00677	CbGeAlD
Atomoxetine—HTR2C—brainstem—epilepsy syndrome	0.000226	0.00673	CbGeAlD
Atomoxetine—SLC6A3—forebrain—epilepsy syndrome	0.000226	0.00672	CbGeAlD
Atomoxetine—NPY1R—brain—epilepsy syndrome	0.000223	0.00662	CbGeAlD
Atomoxetine—HTR1D—forebrain—epilepsy syndrome	0.000221	0.00656	CbGeAlD
Atomoxetine—HTR2C—forebrain—epilepsy syndrome	0.000218	0.00649	CbGeAlD
Atomoxetine—HTR6—head—epilepsy syndrome	0.000216	0.00643	CbGeAlD
Atomoxetine—SLC6A4—brainstem—epilepsy syndrome	0.000215	0.00638	CbGeAlD
Atomoxetine—HTR1B—telencephalon—epilepsy syndrome	0.00021	0.00623	CbGeAlD
Atomoxetine—SLC6A3—telencephalon—epilepsy syndrome	0.000208	0.00618	CbGeAlD
Atomoxetine—SLC6A4—forebrain—epilepsy syndrome	0.000207	0.00616	CbGeAlD
Atomoxetine—HTR6—nervous system—epilepsy syndrome	0.000205	0.0061	CbGeAlD
Atomoxetine—HTR1D—telencephalon—epilepsy syndrome	0.000203	0.00603	CbGeAlD
Atomoxetine—HTR2C—telencephalon—epilepsy syndrome	0.000201	0.00597	CbGeAlD
Atomoxetine—HTR2A—hindbrain—epilepsy syndrome	0.000198	0.00589	CbGeAlD
Atomoxetine—HTR6—central nervous system—epilepsy syndrome	0.000198	0.00587	CbGeAlD
Atomoxetine—SLC6A4—telencephalon—epilepsy syndrome	0.00019	0.00566	CbGeAlD
Atomoxetine—SLC6A2—brainstem—epilepsy syndrome	0.000189	0.00561	CbGeAlD
Atomoxetine—SLC6A2—forebrain—epilepsy syndrome	0.000182	0.00542	CbGeAlD
Atomoxetine—CYP2D6—hindbrain—epilepsy syndrome	0.00018	0.00536	CbGeAlD
Atomoxetine—SLC6A2—telencephalon—epilepsy syndrome	0.000168	0.00498	CbGeAlD
Atomoxetine—HTR2C—medulla oblongata—epilepsy syndrome	0.000158	0.00469	CbGeAlD
Atomoxetine—HTR6—brain—epilepsy syndrome	0.000157	0.00466	CbGeAlD
Atomoxetine—HTR1B—midbrain—epilepsy syndrome	0.00015	0.00447	CbGeAlD
Atomoxetine—SLC6A3—midbrain—epilepsy syndrome	0.000149	0.00444	CbGeAlD
Atomoxetine—HTR1B—spinal cord—epilepsy syndrome	0.000147	0.00436	CbGeAlD
Atomoxetine—HTR1D—midbrain—epilepsy syndrome	0.000146	0.00433	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—epilepsy syndrome	0.000146	0.00433	CbGeAlD
Atomoxetine—HTR2C—midbrain—epilepsy syndrome	0.000144	0.00429	CbGeAlD
Atomoxetine—HTR2C—spinal cord—epilepsy syndrome	0.000141	0.00418	CbGeAlD
Atomoxetine—SLC6A4—midbrain—epilepsy syndrome	0.000137	0.00406	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—epilepsy syndrome	0.000133	0.00397	CbGeAlD
Atomoxetine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000132	0.00392	CbGeAlD
Atomoxetine—HTR1B—head—epilepsy syndrome	0.00013	0.00388	CbGeAlD
Atomoxetine—SLC6A3—head—epilepsy syndrome	0.000129	0.00385	CbGeAlD
Atomoxetine—HTR1D—head—epilepsy syndrome	0.000126	0.00375	CbGeAlD
Atomoxetine—HTR2C—head—epilepsy syndrome	0.000125	0.00372	CbGeAlD
Atomoxetine—HTR1B—nervous system—epilepsy syndrome	0.000124	0.00368	CbGeAlD
Atomoxetine—SLC6A3—nervous system—epilepsy syndrome	0.000123	0.00365	CbGeAlD
Atomoxetine—HTR1D—nervous system—epilepsy syndrome	0.00012	0.00356	CbGeAlD
Atomoxetine—HTR1B—central nervous system—epilepsy syndrome	0.000119	0.00354	CbGeAlD
Atomoxetine—HTR2C—nervous system—epilepsy syndrome	0.000119	0.00352	CbGeAlD
Atomoxetine—SLC6A4—head—epilepsy syndrome	0.000119	0.00352	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—epilepsy syndrome	0.000118	0.00351	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—epilepsy syndrome	0.000115	0.00343	CbGeAlD
Atomoxetine—HTR1D—central nervous system—epilepsy syndrome	0.000115	0.00343	CbGeAlD
Atomoxetine—HTR2C—central nervous system—epilepsy syndrome	0.000114	0.00339	CbGeAlD
Atomoxetine—HTR2A—brainstem—epilepsy syndrome	0.000114	0.00337	CbGeAlD
Atomoxetine—SLC6A4—nervous system—epilepsy syndrome	0.000112	0.00334	CbGeAlD
Atomoxetine—HTR2A—forebrain—epilepsy syndrome	0.00011	0.00326	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—epilepsy syndrome	0.000108	0.00322	CbGeAlD
Atomoxetine—SLC6A2—head—epilepsy syndrome	0.000104	0.0031	CbGeAlD
Atomoxetine—CYP2D6—brainstem—epilepsy syndrome	0.000103	0.00307	CbGeAlD
Atomoxetine—HTR2A—telencephalon—epilepsy syndrome	0.000101	0.003	CbGeAlD
Atomoxetine—CYP2D6—forebrain—epilepsy syndrome	9.98e-05	0.00297	CbGeAlD
Atomoxetine—SLC6A2—nervous system—epilepsy syndrome	9.9e-05	0.00294	CbGeAlD
Atomoxetine—SLC6A2—central nervous system—epilepsy syndrome	9.53e-05	0.00283	CbGeAlD
Atomoxetine—HTR1B—brain—epilepsy syndrome	9.45e-05	0.00281	CbGeAlD
Atomoxetine—SLC6A3—brain—epilepsy syndrome	9.38e-05	0.00279	CbGeAlD
Atomoxetine—CYP2D6—telencephalon—epilepsy syndrome	9.18e-05	0.00273	CbGeAlD
Atomoxetine—HTR1D—brain—epilepsy syndrome	9.15e-05	0.00272	CbGeAlD
Atomoxetine—HTR2C—brain—epilepsy syndrome	9.06e-05	0.00269	CbGeAlD
Atomoxetine—SLC6A4—brain—epilepsy syndrome	8.59e-05	0.00255	CbGeAlD
Atomoxetine—HTR2A—medulla oblongata—epilepsy syndrome	7.92e-05	0.00235	CbGeAlD
Atomoxetine—SLC6A2—brain—epilepsy syndrome	7.57e-05	0.00225	CbGeAlD
Atomoxetine—Doxylamine—CHRM1—epilepsy syndrome	7.41e-05	0.0349	CrCbGaD
Atomoxetine—HTR2A—midbrain—epilepsy syndrome	7.24e-05	0.00215	CbGeAlD
Atomoxetine—HTR2A—spinal cord—epilepsy syndrome	7.06e-05	0.0021	CbGeAlD
Atomoxetine—Orphenadrine—SCN9A—epilepsy syndrome	6.28e-05	0.0296	CrCbGaD
Atomoxetine—HTR2A—head—epilepsy syndrome	6.27e-05	0.00186	CbGeAlD
Atomoxetine—Tolterodine—CHRM3—epilepsy syndrome	6.02e-05	0.0284	CrCbGaD
Atomoxetine—HTR2A—nervous system—epilepsy syndrome	5.95e-05	0.00177	CbGeAlD
Atomoxetine—Orphenadrine—SCN4A—epilepsy syndrome	5.77e-05	0.0272	CrCbGaD
Atomoxetine—HTR2A—central nervous system—epilepsy syndrome	5.73e-05	0.0017	CbGeAlD
Atomoxetine—Ketoprofen—SLCO1A2—epilepsy syndrome	5.72e-05	0.0269	CrCbGaD
Atomoxetine—CYP2D6—head—epilepsy syndrome	5.72e-05	0.0017	CbGeAlD
Atomoxetine—Tolterodine—CHRM1—epilepsy syndrome	5.62e-05	0.0265	CrCbGaD
Atomoxetine—HTR2A—cerebellum—epilepsy syndrome	5.6e-05	0.00166	CbGeAlD
Atomoxetine—CYP3A4—nervous system—epilepsy syndrome	5.51e-05	0.00164	CbGeAlD
Atomoxetine—CYP2D6—nervous system—epilepsy syndrome	5.42e-05	0.00161	CbGeAlD
Atomoxetine—Benzatropine—CHRM1—epilepsy syndrome	5.41e-05	0.0255	CrCbGaD
Atomoxetine—Maprotiline—CHRM3—epilepsy syndrome	5.37e-05	0.0253	CrCbGaD
Atomoxetine—CYP3A4—central nervous system—epilepsy syndrome	5.3e-05	0.00158	CbGeAlD
Atomoxetine—CYP2D6—central nervous system—epilepsy syndrome	5.22e-05	0.00155	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—epilepsy syndrome	5.1e-05	0.00152	CbGeAlD
Atomoxetine—Maprotiline—CHRM1—epilepsy syndrome	5.01e-05	0.0236	CrCbGaD
Atomoxetine—Tolterodine—CHRM2—epilepsy syndrome	4.59e-05	0.0216	CrCbGaD
Atomoxetine—HTR2A—brain—epilepsy syndrome	4.55e-05	0.00135	CbGeAlD
Atomoxetine—Reboxetine—SLC6A4—epilepsy syndrome	4.54e-05	0.0214	CrCbGaD
Atomoxetine—Benzatropine—CHRM2—epilepsy syndrome	4.41e-05	0.0208	CrCbGaD
Atomoxetine—Orphenadrine—SCN1A—epilepsy syndrome	4.22e-05	0.0199	CrCbGaD
Atomoxetine—Ephedrine—BCHE—epilepsy syndrome	4.18e-05	0.0197	CrCbGaD
Atomoxetine—Protriptyline—SLC6A4—epilepsy syndrome	4.17e-05	0.0196	CrCbGaD
Atomoxetine—CYP2D6—brain—epilepsy syndrome	4.14e-05	0.00123	CbGeAlD
Atomoxetine—Maprotiline—CHRM2—epilepsy syndrome	4.09e-05	0.0193	CrCbGaD
Atomoxetine—Maprotiline—HTR7—epilepsy syndrome	4.07e-05	0.0192	CrCbGaD
Atomoxetine—Duloxetine—SLC6A4—epilepsy syndrome	3.49e-05	0.0165	CrCbGaD
Atomoxetine—Methadone—OPRD1—epilepsy syndrome	3.38e-05	0.0159	CrCbGaD
Atomoxetine—Pseudoephedrine—ADRA2A—epilepsy syndrome	3.24e-05	0.0153	CrCbGaD
Atomoxetine—Nortriptyline—CHRM3—epilepsy syndrome	3.22e-05	0.0152	CrCbGaD
Atomoxetine—Reboxetine—CYP2D6—epilepsy syndrome	3.19e-05	0.015	CrCbGaD
Atomoxetine—Pseudoephedrine—TNF—epilepsy syndrome	3.07e-05	0.0145	CrCbGaD
Atomoxetine—Nortriptyline—CHRM1—epilepsy syndrome	3.01e-05	0.0142	CrCbGaD
Atomoxetine—Protriptyline—CYP2D6—epilepsy syndrome	2.93e-05	0.0138	CrCbGaD
Atomoxetine—Fluoxetine—SLC6A4—epilepsy syndrome	2.85e-05	0.0134	CrCbGaD
Atomoxetine—Tolterodine—CYP2C19—epilepsy syndrome	2.83e-05	0.0133	CrCbGaD
Atomoxetine—Benzatropine—CYP2C19—epilepsy syndrome	2.72e-05	0.0128	CrCbGaD
Atomoxetine—Fluoxetine—CYP2C19—epilepsy syndrome	2.7e-05	0.0127	CrCbGaD
Atomoxetine—Duloxetine—HTR2A—epilepsy syndrome	2.69e-05	0.0126	CrCbGaD
Atomoxetine—Desipramine—CHRM3—epilepsy syndrome	2.65e-05	0.0125	CrCbGaD
Atomoxetine—Methadone—OPRM1—epilepsy syndrome	2.59e-05	0.0122	CrCbGaD
Atomoxetine—Desipramine—CHRM1—epilepsy syndrome	2.48e-05	0.0117	CrCbGaD
Atomoxetine—Pseudoephedrine—SLC6A4—epilepsy syndrome	2.47e-05	0.0117	CrCbGaD
Atomoxetine—Warfarin—CYP2C19—epilepsy syndrome	2.46e-05	0.0116	CrCbGaD
Atomoxetine—Duloxetine—CYP2D6—epilepsy syndrome	2.46e-05	0.0116	CrCbGaD
Atomoxetine—Nortriptyline—CHRM2—epilepsy syndrome	2.46e-05	0.0116	CrCbGaD
Atomoxetine—Benzphetamine—ADRA2A—epilepsy syndrome	2.42e-05	0.0114	CrCbGaD
Atomoxetine—Phenoxybenzamine—ADRA2A—epilepsy syndrome	2.31e-05	0.0109	CrCbGaD
Atomoxetine—Reboxetine—ABCB1—epilepsy syndrome	2.28e-05	0.0107	CrCbGaD
Atomoxetine—Diphenhydramine—CHRM2—epilepsy syndrome	2.27e-05	0.0107	CrCbGaD
Atomoxetine—Fluoxetine—HTR2A—epilepsy syndrome	2.19e-05	0.0103	CrCbGaD
Atomoxetine—Headache—Fosphenytoin—epilepsy syndrome	2.18e-05	0.000232	CcSEcCtD
Atomoxetine—Nervous system disorder—Valproic Acid—epilepsy syndrome	2.17e-05	0.000232	CcSEcCtD
Atomoxetine—Palpitations—Pregabalin—epilepsy syndrome	2.17e-05	0.000231	CcSEcCtD
Atomoxetine—Asthenia—Phenytoin—epilepsy syndrome	2.17e-05	0.000231	CcSEcCtD
Atomoxetine—Nausea—Midazolam—epilepsy syndrome	2.17e-05	0.000231	CcSEcCtD
Atomoxetine—Hypoaesthesia—Topiramate—epilepsy syndrome	2.17e-05	0.000231	CcSEcCtD
Atomoxetine—Hallucination—Topiramate—epilepsy syndrome	2.17e-05	0.000231	CcSEcCtD
Atomoxetine—Muscle spasms—Gabapentin—epilepsy syndrome	2.16e-05	0.000231	CcSEcCtD
Atomoxetine—Tachycardia—Valproic Acid—epilepsy syndrome	2.16e-05	0.000231	CcSEcCtD
Atomoxetine—Diarrhoea—Zonisamide—epilepsy syndrome	2.16e-05	0.000231	CcSEcCtD
Atomoxetine—Loss of consciousness—Pregabalin—epilepsy syndrome	2.16e-05	0.00023	CcSEcCtD
Atomoxetine—Asthenia—Oxcarbazepine—epilepsy syndrome	2.16e-05	0.00023	CcSEcCtD
Atomoxetine—Pruritus—Clonazepam—epilepsy syndrome	2.15e-05	0.00023	CcSEcCtD
Atomoxetine—Vomiting—Vigabatrin—epilepsy syndrome	2.15e-05	0.00023	CcSEcCtD
Atomoxetine—Skin disorder—Valproic Acid—epilepsy syndrome	2.15e-05	0.00023	CcSEcCtD
Atomoxetine—Urinary tract disorder—Topiramate—epilepsy syndrome	2.15e-05	0.000229	CcSEcCtD
Atomoxetine—Orphenadrine—CHRM2—epilepsy syndrome	2.15e-05	0.0101	CrCbGaD
Atomoxetine—Hyperhidrosis—Valproic Acid—epilepsy syndrome	2.14e-05	0.000229	CcSEcCtD
Atomoxetine—Cough—Pregabalin—epilepsy syndrome	2.14e-05	0.000229	CcSEcCtD
Atomoxetine—Pruritus—Phenytoin—epilepsy syndrome	2.14e-05	0.000228	CcSEcCtD
Atomoxetine—Nausea—Levetiracetam—epilepsy syndrome	2.14e-05	0.000228	CcSEcCtD
Atomoxetine—Rash—Vigabatrin—epilepsy syndrome	2.14e-05	0.000228	CcSEcCtD
Atomoxetine—Dizziness—Felbamate—epilepsy syndrome	2.13e-05	0.000228	CcSEcCtD
Atomoxetine—Dermatitis—Vigabatrin—epilepsy syndrome	2.13e-05	0.000228	CcSEcCtD
Atomoxetine—Urethral disorder—Topiramate—epilepsy syndrome	2.13e-05	0.000228	CcSEcCtD
Atomoxetine—Pruritus—Oxcarbazepine—epilepsy syndrome	2.13e-05	0.000227	CcSEcCtD
Atomoxetine—Convulsion—Pregabalin—epilepsy syndrome	2.13e-05	0.000227	CcSEcCtD
Atomoxetine—Vision blurred—Gabapentin—epilepsy syndrome	2.12e-05	0.000226	CcSEcCtD
Atomoxetine—Headache—Vigabatrin—epilepsy syndrome	2.12e-05	0.000226	CcSEcCtD
Atomoxetine—Vomiting—Diazepam—epilepsy syndrome	2.12e-05	0.000226	CcSEcCtD
Atomoxetine—Anorexia—Valproic Acid—epilepsy syndrome	2.11e-05	0.000225	CcSEcCtD
Atomoxetine—Tremor—Gabapentin—epilepsy syndrome	2.11e-05	0.000225	CcSEcCtD
Atomoxetine—Rash—Diazepam—epilepsy syndrome	2.1e-05	0.000224	CcSEcCtD
Atomoxetine—Dermatitis—Diazepam—epilepsy syndrome	2.1e-05	0.000224	CcSEcCtD
Atomoxetine—Tolterodine—CYP2D6—epilepsy syndrome	2.1e-05	0.00988	CrCbGaD
Atomoxetine—Protriptyline—ABCB1—epilepsy syndrome	2.09e-05	0.00986	CrCbGaD
Atomoxetine—Myalgia—Pregabalin—epilepsy syndrome	2.09e-05	0.000223	CcSEcCtD
Atomoxetine—Chest pain—Pregabalin—epilepsy syndrome	2.09e-05	0.000223	CcSEcCtD
Atomoxetine—Arthralgia—Pregabalin—epilepsy syndrome	2.09e-05	0.000223	CcSEcCtD
Atomoxetine—Dizziness—Zonisamide—epilepsy syndrome	2.09e-05	0.000223	CcSEcCtD
Atomoxetine—Headache—Diazepam—epilepsy syndrome	2.09e-05	0.000223	CcSEcCtD
Atomoxetine—Anxiety—Pregabalin—epilepsy syndrome	2.08e-05	0.000222	CcSEcCtD
Atomoxetine—Diarrhoea—Clonazepam—epilepsy syndrome	2.08e-05	0.000222	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.08e-05	0.000221	CcSEcCtD
Atomoxetine—Asthenia—Carbamazepine—epilepsy syndrome	2.07e-05	0.000221	CcSEcCtD
Atomoxetine—Agitation—Gabapentin—epilepsy syndrome	2.07e-05	0.000221	CcSEcCtD
Atomoxetine—Diarrhoea—Phenytoin—epilepsy syndrome	2.07e-05	0.000221	CcSEcCtD
Atomoxetine—Nausea—Fosphenytoin—epilepsy syndrome	2.06e-05	0.00022	CcSEcCtD
Atomoxetine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.06e-05	0.00022	CcSEcCtD
Atomoxetine—Vomiting—Felbamate—epilepsy syndrome	2.05e-05	0.000219	CcSEcCtD
Atomoxetine—Maprotiline—HTR2A—epilepsy syndrome	2.05e-05	0.00963	CrCbGaD
Atomoxetine—Dry mouth—Pregabalin—epilepsy syndrome	2.04e-05	0.000218	CcSEcCtD
Atomoxetine—Pruritus—Carbamazepine—epilepsy syndrome	2.04e-05	0.000218	CcSEcCtD
Atomoxetine—Rash—Felbamate—epilepsy syndrome	2.03e-05	0.000217	CcSEcCtD
Atomoxetine—Dermatitis—Felbamate—epilepsy syndrome	2.03e-05	0.000217	CcSEcCtD
Atomoxetine—Vertigo—Gabapentin—epilepsy syndrome	2.02e-05	0.000216	CcSEcCtD
Atomoxetine—Headache—Felbamate—epilepsy syndrome	2.02e-05	0.000216	CcSEcCtD
Atomoxetine—Desipramine—CHRM2—epilepsy syndrome	2.02e-05	0.00952	CrCbGaD
Atomoxetine—Benzatropine—CYP2D6—epilepsy syndrome	2.02e-05	0.00951	CrCbGaD
Atomoxetine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.02e-05	0.000215	CcSEcCtD
Atomoxetine—Flushing—Topiramate—epilepsy syndrome	2.02e-05	0.000215	CcSEcCtD
Atomoxetine—Cardiac disorder—Topiramate—epilepsy syndrome	2.02e-05	0.000215	CcSEcCtD
Atomoxetine—Syncope—Gabapentin—epilepsy syndrome	2.02e-05	0.000215	CcSEcCtD
Atomoxetine—Modafinil—CYP2C19—epilepsy syndrome	2.02e-05	0.0095	CrCbGaD
Atomoxetine—Dizziness—Clonazepam—epilepsy syndrome	2.01e-05	0.000215	CcSEcCtD
Atomoxetine—Nausea—Vigabatrin—epilepsy syndrome	2.01e-05	0.000215	CcSEcCtD
Atomoxetine—Vomiting—Zonisamide—epilepsy syndrome	2.01e-05	0.000214	CcSEcCtD
Atomoxetine—Insomnia—Valproic Acid—epilepsy syndrome	2.01e-05	0.000214	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS2—epilepsy syndrome	2e-05	0.00944	CrCbGaD
Atomoxetine—Fluoxetine—CYP2D6—epilepsy syndrome	2e-05	0.00943	CrCbGaD
Atomoxetine—Asthenia—Lamotrigine—epilepsy syndrome	2e-05	0.000213	CcSEcCtD
Atomoxetine—Dizziness—Phenytoin—epilepsy syndrome	2e-05	0.000213	CcSEcCtD
Atomoxetine—Rash—Zonisamide—epilepsy syndrome	1.99e-05	0.000212	CcSEcCtD
Atomoxetine—Infection—Pregabalin—epilepsy syndrome	1.99e-05	0.000212	CcSEcCtD
Atomoxetine—Paraesthesia—Valproic Acid—epilepsy syndrome	1.99e-05	0.000212	CcSEcCtD
Atomoxetine—Palpitations—Gabapentin—epilepsy syndrome	1.99e-05	0.000212	CcSEcCtD
Atomoxetine—Dermatitis—Zonisamide—epilepsy syndrome	1.99e-05	0.000212	CcSEcCtD
Atomoxetine—Dizziness—Oxcarbazepine—epilepsy syndrome	1.99e-05	0.000212	CcSEcCtD
Atomoxetine—Nausea—Diazepam—epilepsy syndrome	1.98e-05	0.000211	CcSEcCtD
Atomoxetine—Loss of consciousness—Gabapentin—epilepsy syndrome	1.98e-05	0.000211	CcSEcCtD
Atomoxetine—Headache—Zonisamide—epilepsy syndrome	1.98e-05	0.000211	CcSEcCtD
Atomoxetine—Diarrhoea—Carbamazepine—epilepsy syndrome	1.98e-05	0.000211	CcSEcCtD
Atomoxetine—Angiopathy—Topiramate—epilepsy syndrome	1.97e-05	0.000211	CcSEcCtD
Atomoxetine—Pruritus—Lamotrigine—epilepsy syndrome	1.97e-05	0.000211	CcSEcCtD
Atomoxetine—Shock—Pregabalin—epilepsy syndrome	1.97e-05	0.00021	CcSEcCtD
Atomoxetine—Somnolence—Valproic Acid—epilepsy syndrome	1.97e-05	0.00021	CcSEcCtD
Atomoxetine—Nervous system disorder—Pregabalin—epilepsy syndrome	1.97e-05	0.00021	CcSEcCtD
Atomoxetine—Cough—Gabapentin—epilepsy syndrome	1.96e-05	0.00021	CcSEcCtD
Atomoxetine—Mediastinal disorder—Topiramate—epilepsy syndrome	1.96e-05	0.000209	CcSEcCtD
Atomoxetine—Tachycardia—Pregabalin—epilepsy syndrome	1.96e-05	0.000209	CcSEcCtD
Atomoxetine—Chills—Topiramate—epilepsy syndrome	1.95e-05	0.000208	CcSEcCtD
Atomoxetine—Dyspepsia—Valproic Acid—epilepsy syndrome	1.95e-05	0.000208	CcSEcCtD
Atomoxetine—Convulsion—Gabapentin—epilepsy syndrome	1.95e-05	0.000208	CcSEcCtD
Atomoxetine—Skin disorder—Pregabalin—epilepsy syndrome	1.95e-05	0.000208	CcSEcCtD
Atomoxetine—Hyperhidrosis—Pregabalin—epilepsy syndrome	1.94e-05	0.000207	CcSEcCtD
Atomoxetine—Vomiting—Clonazepam—epilepsy syndrome	1.94e-05	0.000206	CcSEcCtD
Atomoxetine—Decreased appetite—Valproic Acid—epilepsy syndrome	1.93e-05	0.000206	CcSEcCtD
Atomoxetine—Vomiting—Phenytoin—epilepsy syndrome	1.92e-05	0.000205	CcSEcCtD
Atomoxetine—Rash—Clonazepam—epilepsy syndrome	1.92e-05	0.000205	CcSEcCtD
Atomoxetine—Dermatitis—Clonazepam—epilepsy syndrome	1.92e-05	0.000205	CcSEcCtD
Atomoxetine—Chest pain—Gabapentin—epilepsy syndrome	1.92e-05	0.000204	CcSEcCtD
Atomoxetine—Myalgia—Gabapentin—epilepsy syndrome	1.92e-05	0.000204	CcSEcCtD
Atomoxetine—Arthralgia—Gabapentin—epilepsy syndrome	1.92e-05	0.000204	CcSEcCtD
Atomoxetine—Nausea—Felbamate—epilepsy syndrome	1.92e-05	0.000204	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Vomiting—Oxcarbazepine—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Fatigue—Valproic Acid—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Anxiety—Gabapentin—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Anorexia—Pregabalin—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Dizziness—Carbamazepine—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Diarrhoea—Lamotrigine—epilepsy syndrome	1.91e-05	0.000204	CcSEcCtD
Atomoxetine—Headache—Clonazepam—epilepsy syndrome	1.91e-05	0.000203	CcSEcCtD
Atomoxetine—Rash—Phenytoin—epilepsy syndrome	1.91e-05	0.000203	CcSEcCtD
Atomoxetine—Mental disorder—Topiramate—epilepsy syndrome	1.91e-05	0.000203	CcSEcCtD
Atomoxetine—Dermatitis—Phenytoin—epilepsy syndrome	1.9e-05	0.000203	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.9e-05	0.000203	CcSEcCtD
Atomoxetine—Rash—Oxcarbazepine—epilepsy syndrome	1.9e-05	0.000202	CcSEcCtD
Atomoxetine—Constipation—Valproic Acid—epilepsy syndrome	1.9e-05	0.000202	CcSEcCtD
Atomoxetine—Pain—Valproic Acid—epilepsy syndrome	1.9e-05	0.000202	CcSEcCtD
Atomoxetine—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.89e-05	0.000202	CcSEcCtD
Atomoxetine—Headache—Phenytoin—epilepsy syndrome	1.89e-05	0.000202	CcSEcCtD
Atomoxetine—Malnutrition—Topiramate—epilepsy syndrome	1.89e-05	0.000202	CcSEcCtD
Atomoxetine—Headache—Oxcarbazepine—epilepsy syndrome	1.88e-05	0.000201	CcSEcCtD
Atomoxetine—Nausea—Zonisamide—epilepsy syndrome	1.88e-05	0.0002	CcSEcCtD
Atomoxetine—Dry mouth—Gabapentin—epilepsy syndrome	1.87e-05	0.0002	CcSEcCtD
Atomoxetine—Maprotiline—CYP2D6—epilepsy syndrome	1.87e-05	0.00881	CrCbGaD
Atomoxetine—Flatulence—Topiramate—epilepsy syndrome	1.87e-05	0.000199	CcSEcCtD
Atomoxetine—Tension—Topiramate—epilepsy syndrome	1.86e-05	0.000198	CcSEcCtD
Atomoxetine—Dysgeusia—Topiramate—epilepsy syndrome	1.86e-05	0.000198	CcSEcCtD
Atomoxetine—Dizziness—Lamotrigine—epilepsy syndrome	1.84e-05	0.000197	CcSEcCtD
Atomoxetine—Nervousness—Topiramate—epilepsy syndrome	1.84e-05	0.000196	CcSEcCtD
Atomoxetine—Vomiting—Carbamazepine—epilepsy syndrome	1.84e-05	0.000196	CcSEcCtD
Atomoxetine—Back pain—Topiramate—epilepsy syndrome	1.83e-05	0.000195	CcSEcCtD
Atomoxetine—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.83e-05	0.000195	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.83e-05	0.000195	CcSEcCtD
Atomoxetine—Infection—Gabapentin—epilepsy syndrome	1.83e-05	0.000195	CcSEcCtD
Atomoxetine—Muscle spasms—Topiramate—epilepsy syndrome	1.82e-05	0.000194	CcSEcCtD
Atomoxetine—Rash—Carbamazepine—epilepsy syndrome	1.82e-05	0.000194	CcSEcCtD
Atomoxetine—Dermatitis—Carbamazepine—epilepsy syndrome	1.82e-05	0.000194	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.81e-05	0.000193	CcSEcCtD
Atomoxetine—Insomnia—Pregabalin—epilepsy syndrome	1.81e-05	0.000193	CcSEcCtD
Atomoxetine—Nausea—Clonazepam—epilepsy syndrome	1.81e-05	0.000193	CcSEcCtD
Atomoxetine—Headache—Carbamazepine—epilepsy syndrome	1.81e-05	0.000193	CcSEcCtD
Atomoxetine—Shock—Gabapentin—epilepsy syndrome	1.81e-05	0.000193	CcSEcCtD
Atomoxetine—Nervous system disorder—Gabapentin—epilepsy syndrome	1.8e-05	0.000192	CcSEcCtD
Atomoxetine—Paraesthesia—Pregabalin—epilepsy syndrome	1.8e-05	0.000192	CcSEcCtD
Atomoxetine—Nausea—Phenytoin—epilepsy syndrome	1.8e-05	0.000192	CcSEcCtD
Atomoxetine—Tachycardia—Gabapentin—epilepsy syndrome	1.79e-05	0.000191	CcSEcCtD
Atomoxetine—Nausea—Oxcarbazepine—epilepsy syndrome	1.79e-05	0.000191	CcSEcCtD
Atomoxetine—Fenoprofen—ALB—epilepsy syndrome	1.79e-05	0.00841	CrCbGaD
Atomoxetine—Vision blurred—Topiramate—epilepsy syndrome	1.79e-05	0.00019	CcSEcCtD
Atomoxetine—Skin disorder—Gabapentin—epilepsy syndrome	1.79e-05	0.00019	CcSEcCtD
Atomoxetine—Propafenone—CYP2D6—epilepsy syndrome	1.78e-05	0.0084	CrCbGaD
Atomoxetine—Somnolence—Pregabalin—epilepsy syndrome	1.78e-05	0.00019	CcSEcCtD
Atomoxetine—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.78e-05	0.000189	CcSEcCtD
Atomoxetine—Tremor—Topiramate—epilepsy syndrome	1.77e-05	0.000189	CcSEcCtD
Atomoxetine—Vomiting—Lamotrigine—epilepsy syndrome	1.77e-05	0.000189	CcSEcCtD
Atomoxetine—Urticaria—Valproic Acid—epilepsy syndrome	1.76e-05	0.000188	CcSEcCtD
Atomoxetine—Rash—Lamotrigine—epilepsy syndrome	1.76e-05	0.000188	CcSEcCtD
Atomoxetine—Dermatitis—Lamotrigine—epilepsy syndrome	1.76e-05	0.000187	CcSEcCtD
Atomoxetine—Abdominal pain—Valproic Acid—epilepsy syndrome	1.75e-05	0.000187	CcSEcCtD
Atomoxetine—Body temperature increased—Valproic Acid—epilepsy syndrome	1.75e-05	0.000187	CcSEcCtD
Atomoxetine—Anorexia—Gabapentin—epilepsy syndrome	1.75e-05	0.000187	CcSEcCtD
Atomoxetine—Headache—Lamotrigine—epilepsy syndrome	1.75e-05	0.000186	CcSEcCtD
Atomoxetine—Decreased appetite—Pregabalin—epilepsy syndrome	1.74e-05	0.000186	CcSEcCtD
Atomoxetine—Agitation—Topiramate—epilepsy syndrome	1.74e-05	0.000186	CcSEcCtD
Atomoxetine—Pseudoephedrine—CYP2D6—epilepsy syndrome	1.74e-05	0.00819	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.73e-05	0.000185	CcSEcCtD
Atomoxetine—Fatigue—Pregabalin—epilepsy syndrome	1.73e-05	0.000184	CcSEcCtD
Atomoxetine—Nausea—Carbamazepine—epilepsy syndrome	1.71e-05	0.000183	CcSEcCtD
Atomoxetine—Pain—Pregabalin—epilepsy syndrome	1.71e-05	0.000183	CcSEcCtD
Atomoxetine—Constipation—Pregabalin—epilepsy syndrome	1.71e-05	0.000183	CcSEcCtD
Atomoxetine—Vertigo—Topiramate—epilepsy syndrome	1.7e-05	0.000182	CcSEcCtD
Atomoxetine—Syncope—Topiramate—epilepsy syndrome	1.7e-05	0.000181	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.67e-05	0.000179	CcSEcCtD
Atomoxetine—Palpitations—Topiramate—epilepsy syndrome	1.67e-05	0.000179	CcSEcCtD
Atomoxetine—Loss of consciousness—Topiramate—epilepsy syndrome	1.67e-05	0.000178	CcSEcCtD
Atomoxetine—Insomnia—Gabapentin—epilepsy syndrome	1.66e-05	0.000177	CcSEcCtD
Atomoxetine—Nausea—Lamotrigine—epilepsy syndrome	1.66e-05	0.000177	CcSEcCtD
Atomoxetine—Cough—Topiramate—epilepsy syndrome	1.65e-05	0.000176	CcSEcCtD
Atomoxetine—Feeling abnormal—Pregabalin—epilepsy syndrome	1.65e-05	0.000176	CcSEcCtD
Atomoxetine—Paraesthesia—Gabapentin—epilepsy syndrome	1.65e-05	0.000176	CcSEcCtD
Atomoxetine—Propranolol—CYP2C19—epilepsy syndrome	1.65e-05	0.00776	CrCbGaD
Atomoxetine—Convulsion—Topiramate—epilepsy syndrome	1.64e-05	0.000175	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.64e-05	0.000175	CcSEcCtD
Atomoxetine—Somnolence—Gabapentin—epilepsy syndrome	1.63e-05	0.000174	CcSEcCtD
Atomoxetine—Dyspepsia—Gabapentin—epilepsy syndrome	1.62e-05	0.000173	CcSEcCtD
Atomoxetine—Chest pain—Topiramate—epilepsy syndrome	1.61e-05	0.000172	CcSEcCtD
Atomoxetine—Myalgia—Topiramate—epilepsy syndrome	1.61e-05	0.000172	CcSEcCtD
Atomoxetine—Arthralgia—Topiramate—epilepsy syndrome	1.61e-05	0.000172	CcSEcCtD
Atomoxetine—Anxiety—Topiramate—epilepsy syndrome	1.61e-05	0.000171	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.6e-05	0.000171	CcSEcCtD
Atomoxetine—Nortriptyline—SLC6A4—epilepsy syndrome	1.6e-05	0.00753	CrCbGaD
Atomoxetine—Decreased appetite—Gabapentin—epilepsy syndrome	1.6e-05	0.00017	CcSEcCtD
Atomoxetine—Urticaria—Pregabalin—epilepsy syndrome	1.59e-05	0.00017	CcSEcCtD
Atomoxetine—Asthenia—Valproic Acid—epilepsy syndrome	1.59e-05	0.00017	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.59e-05	0.000169	CcSEcCtD
Atomoxetine—Fatigue—Gabapentin—epilepsy syndrome	1.58e-05	0.000169	CcSEcCtD
Atomoxetine—Abdominal pain—Pregabalin—epilepsy syndrome	1.58e-05	0.000169	CcSEcCtD
Atomoxetine—Body temperature increased—Pregabalin—epilepsy syndrome	1.58e-05	0.000169	CcSEcCtD
Atomoxetine—Dry mouth—Topiramate—epilepsy syndrome	1.58e-05	0.000168	CcSEcCtD
Atomoxetine—Constipation—Gabapentin—epilepsy syndrome	1.57e-05	0.000168	CcSEcCtD
Atomoxetine—Pain—Gabapentin—epilepsy syndrome	1.57e-05	0.000168	CcSEcCtD
Atomoxetine—Pruritus—Valproic Acid—epilepsy syndrome	1.57e-05	0.000167	CcSEcCtD
Atomoxetine—Phenprocoumon—ALB—epilepsy syndrome	1.54e-05	0.00725	CrCbGaD
Atomoxetine—Infection—Topiramate—epilepsy syndrome	1.54e-05	0.000164	CcSEcCtD
Atomoxetine—Shock—Topiramate—epilepsy syndrome	1.52e-05	0.000162	CcSEcCtD
Atomoxetine—Diarrhoea—Valproic Acid—epilepsy syndrome	1.52e-05	0.000162	CcSEcCtD
Atomoxetine—Nervous system disorder—Topiramate—epilepsy syndrome	1.52e-05	0.000162	CcSEcCtD
Atomoxetine—Nortriptyline—CYP2C19—epilepsy syndrome	1.52e-05	0.00714	CrCbGaD
Atomoxetine—Feeling abnormal—Gabapentin—epilepsy syndrome	1.51e-05	0.000162	CcSEcCtD
Atomoxetine—Tachycardia—Topiramate—epilepsy syndrome	1.51e-05	0.000161	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.5e-05	0.00016	CcSEcCtD
Atomoxetine—Skin disorder—Topiramate—epilepsy syndrome	1.5e-05	0.00016	CcSEcCtD
Atomoxetine—Fluoxetine—ALB—epilepsy syndrome	1.5e-05	0.00705	CrCbGaD
Atomoxetine—Hyperhidrosis—Topiramate—epilepsy syndrome	1.49e-05	0.000159	CcSEcCtD
Atomoxetine—Anorexia—Topiramate—epilepsy syndrome	1.47e-05	0.000157	CcSEcCtD
Atomoxetine—Dizziness—Valproic Acid—epilepsy syndrome	1.47e-05	0.000156	CcSEcCtD
Atomoxetine—Urticaria—Gabapentin—epilepsy syndrome	1.46e-05	0.000156	CcSEcCtD
Atomoxetine—Body temperature increased—Gabapentin—epilepsy syndrome	1.45e-05	0.000155	CcSEcCtD
Atomoxetine—Abdominal pain—Gabapentin—epilepsy syndrome	1.45e-05	0.000155	CcSEcCtD
Atomoxetine—Asthenia—Pregabalin—epilepsy syndrome	1.44e-05	0.000153	CcSEcCtD
Atomoxetine—Fluoxetine—ABCB1—epilepsy syndrome	1.43e-05	0.00673	CrCbGaD
Atomoxetine—Pruritus—Pregabalin—epilepsy syndrome	1.42e-05	0.000151	CcSEcCtD
Atomoxetine—Vomiting—Valproic Acid—epilepsy syndrome	1.41e-05	0.00015	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.41e-05	0.00015	CcSEcCtD
Atomoxetine—Diphenhydramine—CYP2C19—epilepsy syndrome	1.4e-05	0.0066	CrCbGaD
Atomoxetine—Insomnia—Topiramate—epilepsy syndrome	1.4e-05	0.000149	CcSEcCtD
Atomoxetine—Rash—Valproic Acid—epilepsy syndrome	1.4e-05	0.000149	CcSEcCtD
Atomoxetine—Dermatitis—Valproic Acid—epilepsy syndrome	1.4e-05	0.000149	CcSEcCtD
Atomoxetine—Headache—Valproic Acid—epilepsy syndrome	1.39e-05	0.000148	CcSEcCtD
Atomoxetine—Paraesthesia—Topiramate—epilepsy syndrome	1.39e-05	0.000148	CcSEcCtD
Atomoxetine—Somnolence—Topiramate—epilepsy syndrome	1.37e-05	0.000147	CcSEcCtD
Atomoxetine—Diarrhoea—Pregabalin—epilepsy syndrome	1.37e-05	0.000146	CcSEcCtD
Atomoxetine—Warfarin—ALB—epilepsy syndrome	1.37e-05	0.00643	CrCbGaD
Atomoxetine—Dyspepsia—Topiramate—epilepsy syndrome	1.36e-05	0.000145	CcSEcCtD
Atomoxetine—Methadone—CYP2C19—epilepsy syndrome	1.35e-05	0.00637	CrCbGaD
Atomoxetine—Decreased appetite—Topiramate—epilepsy syndrome	1.34e-05	0.000143	CcSEcCtD
Atomoxetine—Maprotiline—ABCB1—epilepsy syndrome	1.34e-05	0.00629	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.33e-05	0.000142	CcSEcCtD
Atomoxetine—Fatigue—Topiramate—epilepsy syndrome	1.33e-05	0.000142	CcSEcCtD
Atomoxetine—Dizziness—Pregabalin—epilepsy syndrome	1.33e-05	0.000141	CcSEcCtD
Atomoxetine—Constipation—Topiramate—epilepsy syndrome	1.32e-05	0.000141	CcSEcCtD
Atomoxetine—Pain—Topiramate—epilepsy syndrome	1.32e-05	0.000141	CcSEcCtD
Atomoxetine—Asthenia—Gabapentin—epilepsy syndrome	1.32e-05	0.000141	CcSEcCtD
Atomoxetine—Nausea—Valproic Acid—epilepsy syndrome	1.32e-05	0.00014	CcSEcCtD
Atomoxetine—Desipramine—SLC6A4—epilepsy syndrome	1.32e-05	0.0062	CrCbGaD
Atomoxetine—Pruritus—Gabapentin—epilepsy syndrome	1.3e-05	0.000139	CcSEcCtD
Atomoxetine—Vomiting—Pregabalin—epilepsy syndrome	1.27e-05	0.000136	CcSEcCtD
Atomoxetine—Propafenone—ABCB1—epilepsy syndrome	1.27e-05	0.006	CrCbGaD
Atomoxetine—Feeling abnormal—Topiramate—epilepsy syndrome	1.27e-05	0.000136	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.26e-05	0.000135	CcSEcCtD
Atomoxetine—Rash—Pregabalin—epilepsy syndrome	1.26e-05	0.000135	CcSEcCtD
Atomoxetine—Dermatitis—Pregabalin—epilepsy syndrome	1.26e-05	0.000135	CcSEcCtD
Atomoxetine—Diarrhoea—Gabapentin—epilepsy syndrome	1.26e-05	0.000134	CcSEcCtD
Atomoxetine—Headache—Pregabalin—epilepsy syndrome	1.26e-05	0.000134	CcSEcCtD
Atomoxetine—Desipramine—CYP2C19—epilepsy syndrome	1.25e-05	0.00588	CrCbGaD
Atomoxetine—Nortriptyline—HTR2A—epilepsy syndrome	1.23e-05	0.00579	CrCbGaD
Atomoxetine—Urticaria—Topiramate—epilepsy syndrome	1.23e-05	0.000131	CcSEcCtD
Atomoxetine—Body temperature increased—Topiramate—epilepsy syndrome	1.22e-05	0.00013	CcSEcCtD
Atomoxetine—Abdominal pain—Topiramate—epilepsy syndrome	1.22e-05	0.00013	CcSEcCtD
Atomoxetine—Propranolol—CYP2D6—epilepsy syndrome	1.22e-05	0.00575	CrCbGaD
Atomoxetine—Dizziness—Gabapentin—epilepsy syndrome	1.22e-05	0.00013	CcSEcCtD
Atomoxetine—Nausea—Pregabalin—epilepsy syndrome	1.19e-05	0.000127	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—epilepsy syndrome	1.18e-05	0.00557	CrCbGaD
Atomoxetine—Vomiting—Gabapentin—epilepsy syndrome	1.17e-05	0.000125	CcSEcCtD
Atomoxetine—Rash—Gabapentin—epilepsy syndrome	1.16e-05	0.000124	CcSEcCtD
Atomoxetine—Dermatitis—Gabapentin—epilepsy syndrome	1.16e-05	0.000123	CcSEcCtD
Atomoxetine—Headache—Gabapentin—epilepsy syndrome	1.15e-05	0.000123	CcSEcCtD
Atomoxetine—Nortriptyline—CYP2D6—epilepsy syndrome	1.12e-05	0.00529	CrCbGaD
Atomoxetine—Asthenia—Topiramate—epilepsy syndrome	1.11e-05	0.000118	CcSEcCtD
Atomoxetine—Pruritus—Topiramate—epilepsy syndrome	1.09e-05	0.000117	CcSEcCtD
Atomoxetine—Nausea—Gabapentin—epilepsy syndrome	1.09e-05	0.000116	CcSEcCtD
Atomoxetine—Diarrhoea—Topiramate—epilepsy syndrome	1.06e-05	0.000113	CcSEcCtD
Atomoxetine—Ketoprofen—ALB—epilepsy syndrome	1.05e-05	0.00496	CrCbGaD
Atomoxetine—Diphenhydramine—CYP2D6—epilepsy syndrome	1.04e-05	0.00489	CrCbGaD
Atomoxetine—Dizziness—Topiramate—epilepsy syndrome	1.02e-05	0.000109	CcSEcCtD
Atomoxetine—Desipramine—HTR2A—epilepsy syndrome	1.01e-05	0.00476	CrCbGaD
Atomoxetine—Methadone—CYP2D6—epilepsy syndrome	1e-05	0.00472	CrCbGaD
Atomoxetine—Vomiting—Topiramate—epilepsy syndrome	9.83e-06	0.000105	CcSEcCtD
Atomoxetine—Rash—Topiramate—epilepsy syndrome	9.75e-06	0.000104	CcSEcCtD
Atomoxetine—Dermatitis—Topiramate—epilepsy syndrome	9.74e-06	0.000104	CcSEcCtD
Atomoxetine—Headache—Topiramate—epilepsy syndrome	9.69e-06	0.000103	CcSEcCtD
Atomoxetine—Desipramine—CYP2D6—epilepsy syndrome	9.25e-06	0.00436	CrCbGaD
Atomoxetine—Nausea—Topiramate—epilepsy syndrome	9.18e-06	9.8e-05	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—epilepsy syndrome	8.72e-06	0.00411	CrCbGaD
Atomoxetine—Nortriptyline—ALB—epilepsy syndrome	8.41e-06	0.00396	CrCbGaD
Atomoxetine—Methadone—ABCB1—epilepsy syndrome	7.16e-06	0.00337	CrCbGaD
Atomoxetine—Desipramine—ABCB1—epilepsy syndrome	6.61e-06	0.00311	CrCbGaD
Atomoxetine—HTR2C—Signaling by GPCR—PRKCB—epilepsy syndrome	1.96e-06	3.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—H2AFX—epilepsy syndrome	1.96e-06	3.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MEF2C—epilepsy syndrome	1.96e-06	3.83e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	1.96e-06	3.82e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6ST—epilepsy syndrome	1.95e-06	3.82e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUNB—epilepsy syndrome	1.93e-06	3.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CNR1—epilepsy syndrome	1.93e-06	3.78e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FYN—epilepsy syndrome	1.93e-06	3.77e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PLCB1—epilepsy syndrome	1.93e-06	3.77e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—H2AFX—epilepsy syndrome	1.92e-06	3.75e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MEF2C—epilepsy syndrome	1.92e-06	3.75e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—YWHAZ—epilepsy syndrome	1.91e-06	3.73e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—YWHAZ—epilepsy syndrome	1.89e-06	3.7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GBE1—epilepsy syndrome	1.89e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	1.89e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR7—epilepsy syndrome	1.89e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NGF—epilepsy syndrome	1.88e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.88e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.88e-06	3.67e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NGF—epilepsy syndrome	1.87e-06	3.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC1—epilepsy syndrome	1.87e-06	3.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTK2B—epilepsy syndrome	1.87e-06	3.66e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	1.86e-06	3.64e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	1.86e-06	3.64e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—YWHAZ—epilepsy syndrome	1.85e-06	3.62e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.85e-06	3.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGT—epilepsy syndrome	1.84e-06	3.6e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCR5—epilepsy syndrome	1.83e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NGF—epilepsy syndrome	1.83e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HBEGF—epilepsy syndrome	1.83e-06	3.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SST—epilepsy syndrome	1.82e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR2—epilepsy syndrome	1.82e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK2—epilepsy syndrome	1.82e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCR5—epilepsy syndrome	1.82e-06	3.56e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DUSP6—epilepsy syndrome	1.8e-06	3.53e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT3—epilepsy syndrome	1.8e-06	3.51e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—epilepsy syndrome	1.79e-06	3.51e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—epilepsy syndrome	1.79e-06	3.49e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCR5—epilepsy syndrome	1.78e-06	3.48e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRA2A—epilepsy syndrome	1.78e-06	3.48e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—epilepsy syndrome	1.78e-06	3.48e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	1.78e-06	3.47e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLAT—epilepsy syndrome	1.77e-06	3.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADAM10—epilepsy syndrome	1.76e-06	3.43e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL2—epilepsy syndrome	1.75e-06	3.42e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—epilepsy syndrome	1.74e-06	3.41e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	1.73e-06	3.38e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BDKRB2—epilepsy syndrome	1.71e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL12—epilepsy syndrome	1.71e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—epilepsy syndrome	1.71e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSC2—epilepsy syndrome	1.7e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PRKCB—epilepsy syndrome	1.7e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGT—epilepsy syndrome	1.7e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6ST—epilepsy syndrome	1.7e-06	3.32e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSC2—epilepsy syndrome	1.69e-06	3.31e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGT—epilepsy syndrome	1.69e-06	3.3e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NT5E—epilepsy syndrome	1.68e-06	3.29e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALAD—epilepsy syndrome	1.68e-06	3.29e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUNB—epilepsy syndrome	1.68e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CNR1—epilepsy syndrome	1.68e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLCB1—epilepsy syndrome	1.67e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—epilepsy syndrome	1.67e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—S100B—epilepsy syndrome	1.66e-06	3.25e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSC2—epilepsy syndrome	1.66e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—epilepsy syndrome	1.66e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGT—epilepsy syndrome	1.65e-06	3.23e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	1.65e-06	3.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SOCS3—epilepsy syndrome	1.64e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDC42—epilepsy syndrome	1.64e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR7—epilepsy syndrome	1.64e-06	3.2e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KDR—epilepsy syndrome	1.63e-06	3.19e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KDR—epilepsy syndrome	1.62e-06	3.17e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—epilepsy syndrome	1.62e-06	3.17e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	1.61e-06	3.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	1.61e-06	3.14e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	1.6e-06	3.12e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HBEGF—epilepsy syndrome	1.59e-06	3.11e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KDR—epilepsy syndrome	1.59e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AVP—epilepsy syndrome	1.59e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.59e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRKCB—epilepsy syndrome	1.57e-06	3.07e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	1.57e-06	3.07e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6ST—epilepsy syndrome	1.57e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT3—epilepsy syndrome	1.56e-06	3.05e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRKCB—epilepsy syndrome	1.56e-06	3.05e-05	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKT1—epilepsy syndrome	1.56e-06	3.04e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6ST—epilepsy syndrome	1.55e-06	3.04e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—epilepsy syndrome	1.55e-06	3.03e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.54e-06	3.01e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRKCB—epilepsy syndrome	1.53e-06	2.99e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADAM10—epilepsy syndrome	1.52e-06	2.98e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6ST—epilepsy syndrome	1.52e-06	2.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL2—epilepsy syndrome	1.52e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.52e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.51e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HES1—epilepsy syndrome	1.5e-06	2.94e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.48e-06	2.9e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.48e-06	2.89e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.47e-06	2.87e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FYN—epilepsy syndrome	1.46e-06	2.85e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—H2AFX—epilepsy syndrome	1.45e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MEF2C—epilepsy syndrome	1.45e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.45e-06	2.83e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—S100B—epilepsy syndrome	1.44e-06	2.82e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	1.44e-06	2.82e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—epilepsy syndrome	1.43e-06	2.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SOCS3—epilepsy syndrome	1.43e-06	2.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDC42—epilepsy syndrome	1.42e-06	2.78e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—epilepsy syndrome	1.42e-06	2.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—YWHAZ—epilepsy syndrome	1.4e-06	2.74e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL2—epilepsy syndrome	1.4e-06	2.74e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—epilepsy syndrome	1.39e-06	2.72e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL2—epilepsy syndrome	1.39e-06	2.72e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NGF—epilepsy syndrome	1.39e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.39e-06	2.71e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AVP—epilepsy syndrome	1.38e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	1.37e-06	2.68e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BCHE—epilepsy syndrome	1.37e-06	2.67e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL2—epilepsy syndrome	1.36e-06	2.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR5—epilepsy syndrome	1.35e-06	2.64e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.35e-06	2.63e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—epilepsy syndrome	1.32e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HES1—epilepsy syndrome	1.3e-06	2.55e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	1.3e-06	2.55e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	1.29e-06	2.52e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TH—epilepsy syndrome	1.29e-06	2.51e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FYN—epilepsy syndrome	1.27e-06	2.48e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FGF2—epilepsy syndrome	1.27e-06	2.48e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.27e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—H2AFX—epilepsy syndrome	1.26e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.26e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MEF2C—epilepsy syndrome	1.26e-06	2.47e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FGF2—epilepsy syndrome	1.26e-06	2.46e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.26e-06	2.46e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSC2—epilepsy syndrome	1.26e-06	2.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGT—epilepsy syndrome	1.25e-06	2.45e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FGF2—epilepsy syndrome	1.23e-06	2.41e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—epilepsy syndrome	1.23e-06	2.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—YWHAZ—epilepsy syndrome	1.22e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.22e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.22e-06	2.38e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NGF—epilepsy syndrome	1.21e-06	2.36e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KDR—epilepsy syndrome	1.2e-06	2.35e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.2e-06	2.34e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.19e-06	2.32e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TH—epilepsy syndrome	1.18e-06	2.31e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RELA—epilepsy syndrome	1.18e-06	2.3e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR5—epilepsy syndrome	1.17e-06	2.29e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RELA—epilepsy syndrome	1.17e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKCB—epilepsy syndrome	1.16e-06	2.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6ST—epilepsy syndrome	1.15e-06	2.26e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MTOR—epilepsy syndrome	1.15e-06	2.25e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MTOR—epilepsy syndrome	1.14e-06	2.24e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RELA—epilepsy syndrome	1.14e-06	2.23e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MTOR—epilepsy syndrome	1.12e-06	2.19e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC2—epilepsy syndrome	1.09e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGT—epilepsy syndrome	1.09e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	1.07e-06	2.1e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—epilepsy syndrome	1.07e-06	2.09e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—epilepsy syndrome	1.07e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—epilepsy syndrome	1.06e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—epilepsy syndrome	1.06e-06	2.07e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAT—epilepsy syndrome	1.06e-06	2.07e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—epilepsy syndrome	1.06e-06	2.06e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—epilepsy syndrome	1.05e-06	2.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—epilepsy syndrome	1.05e-06	2.04e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—epilepsy syndrome	1.04e-06	2.03e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—epilepsy syndrome	1.03e-06	2.02e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—epilepsy syndrome	1.03e-06	2.02e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—epilepsy syndrome	1.03e-06	2.01e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	1.03e-06	2.01e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—epilepsy syndrome	1.02e-06	2e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKCB—epilepsy syndrome	1.01e-06	1.97e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—epilepsy syndrome	1e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6ST—epilepsy syndrome	1e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—epilepsy syndrome	1e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—epilepsy syndrome	9.95e-07	1.94e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	9.92e-07	1.94e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	9.86e-07	1.93e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—epilepsy syndrome	9.74e-07	1.9e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAT—epilepsy syndrome	9.73e-07	1.9e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—epilepsy syndrome	9.72e-07	1.9e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	9.67e-07	1.89e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—epilepsy syndrome	9.65e-07	1.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	9.61e-07	1.88e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—epilepsy syndrome	9.57e-07	1.87e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	9.47e-07	1.85e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—epilepsy syndrome	9.45e-07	1.85e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGF2—epilepsy syndrome	9.33e-07	1.82e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SRC—epilepsy syndrome	9.24e-07	1.81e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SRC—epilepsy syndrome	9.17e-07	1.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—epilepsy syndrome	9.16e-07	1.79e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—epilepsy syndrome	9e-07	1.76e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SRC—epilepsy syndrome	8.98e-07	1.76e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—epilepsy syndrome	8.97e-07	1.75e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—epilepsy syndrome	8.93e-07	1.75e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—epilepsy syndrome	8.8e-07	1.72e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—epilepsy syndrome	8.75e-07	1.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	8.67e-07	1.69e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RELA—epilepsy syndrome	8.66e-07	1.69e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTOR—epilepsy syndrome	8.49e-07	1.66e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGT—epilepsy syndrome	8.39e-07	1.64e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	8.25e-07	1.61e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—epilepsy syndrome	8.22e-07	1.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BCHE—epilepsy syndrome	8.22e-07	1.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGF2—epilepsy syndrome	8.1e-07	1.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—epilepsy syndrome	7.89e-07	1.54e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	7.84e-07	1.53e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—epilepsy syndrome	7.81e-07	1.53e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	7.76e-07	1.52e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TH—epilepsy syndrome	7.73e-07	1.51e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGT—epilepsy syndrome	7.72e-07	1.51e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—epilepsy syndrome	7.59e-07	1.48e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—epilepsy syndrome	7.56e-07	1.48e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RELA—epilepsy syndrome	7.52e-07	1.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—epilepsy syndrome	7.38e-07	1.44e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTOR—epilepsy syndrome	7.38e-07	1.44e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—epilepsy syndrome	7.16e-07	1.4e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—epilepsy syndrome	7.06e-07	1.38e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—epilepsy syndrome	6.85e-07	1.34e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SRC—epilepsy syndrome	6.81e-07	1.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—epilepsy syndrome	6.78e-07	1.33e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—epilepsy syndrome	6.63e-07	1.3e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—epilepsy syndrome	6.59e-07	1.29e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—epilepsy syndrome	6.5e-07	1.27e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	6.45e-07	1.26e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—epilepsy syndrome	6.44e-07	1.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—epilepsy syndrome	6.41e-07	1.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAT—epilepsy syndrome	6.36e-07	1.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—epilepsy syndrome	6.22e-07	1.22e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	6.19e-07	1.21e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—epilepsy syndrome	5.92e-07	1.16e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SRC—epilepsy syndrome	5.91e-07	1.16e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—epilepsy syndrome	5.76e-07	1.13e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—epilepsy syndrome	5.76e-07	1.12e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—epilepsy syndrome	5.74e-07	1.12e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—epilepsy syndrome	5.7e-07	1.11e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	5.63e-07	1.1e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—epilepsy syndrome	5.58e-07	1.09e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	5.18e-07	1.01e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGT—epilepsy syndrome	5.05e-07	9.86e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—epilepsy syndrome	4.94e-07	9.66e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—epilepsy syndrome	4.25e-07	8.3e-06	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—epilepsy syndrome	4.23e-07	8.27e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—epilepsy syndrome	3.87e-07	7.57e-06	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—epilepsy syndrome	3.67e-07	7.18e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	3.39e-07	6.62e-06	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—epilepsy syndrome	2.83e-07	5.53e-06	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—epilepsy syndrome	2.6e-07	5.09e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.7e-07	3.33e-06	CbGpPWpGaD
